Healthcare Industry News: ultrasound
News Release - March 3, 2011
Celleration Inc. Announces Award-Winning Clinical Results to Reduce Unfavorable Deep Tissue Injury OutcomesEDEN PRAIRIE, Minn., March 3, 2011 -- (Healthcare Sales & Marketing Network) -- Celleration Inc., a privately held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies, announced the release of award-winning clinical results at the 2011 National Pressure Ulcer Advisory Panel (NPUAP) Biannual meeting in Las Vegas using MISTŪ ultrasound Healing Therapy. The clinical results using MIST Therapy to treat deep tissue injuries(DTI), a form of pressure ulcer or bed sore, were so compelling that the poster was awarded NPUAP's top award for contribution to the field of pressure ulcer research.
The retrospective analysis was conducted at Central Baptist Hospital in Lexington, Kentucky and included 85 patients with a total of 127 deep tissue injuries. The control group received standard of care, while the treatment group added MIST Therapy to the standard of care. In the MIST Therapy group 80% demonstrated a favorable outcome, while only 22% of the control group demonstrated a favorable outcome. There was a complete reversal of favorable to unfavorable outcomes between the two groups. Joyce Black, Associate Professor in the College of Nursing at the University of Nebraska Medical Center and Past President of the NPUAP states, "Deep tissue injury is recognized today as the cause of some of the worse pressure ulcers we see. We had come to believe that there was not much we could do to reverse the tissue loss, but the Central Baptist data should cause all of us to rethink our treatments for DTI."
MIST Therapy is a noncontact, low frequency ultrasound that is delivered through a saline mist. Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers energy deep into the wound bed to rescue injured cells and minimize tissue loss through reducing inflammation and promoting the body's normal healing process. "We are very pleased with the results of MIST Therapy in treating deep tissue injuries and the ability of MIST to provide a treatment solution where none has previously existed," stated Mark Wagner, CEO of Celleration.
A deep tissue injury (DTI) is a type of pressure ulcer that results in injury deep below the surface, but is not visible until days later. The injury then progresses very rapidly to a deep, open wound called a Stage III or IV pressure ulcer, which is considered an unfavorable outcome. DTI's are a common occurrence in US hospitals with average prevalence rates of 7% to 9%. In 2008, the Center for Medicare Services (CMS) stopped paying for hospital-acquired conditions they felt were the results of poor quality care, commonly known as "never events". Stage III and IV pressure ulcers, a common outcome of deep tissue injuries, are included on the list of "never events".
For more information visit www.celleration.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.